-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The artificial joint national procurement, which has attracted much attention in the industry, has announced the results of the proposed selection on the evening of September 14.
A total of 44 companies have been selected in this centralized procurement, and the artificial joint products to be selected have an average price reduction of 82%
.
As soon as the news came out, the stock prices of related listed companies rose sharply
.
On September 14, Weigao Orthopaedic’s share price in the A-share market was at the daily limit and closed up 19%; Dabo Medical rose by the limit in the afternoon; Hong Kong stock Aikang Medical rose by more than 20%, and MicroPort Medical and Chunli Medical also increased by more than 10%.
.
Recently, the overall trend of the medical device sector is still relatively strong.
According to the news on September 17, the sector has risen.
In terms of individual stocks, Weigao Orthopedics and MicroPort Medical have risen by more than 4%.
In addition, Dabo Medical and Chunli Medical have also followed suit.
.
Weigao Orthopedics rose 4.
27% As of press time, Weigao Orthopaedic rose 4.
27% to 78.
80 yuan, with a turnover of 215 million and a turnover rate of 8.
16%.
The current total market value is 31.
520 billion
.
According to public information, Weigao Orthopaedic's main business is the research and development, production and sales of orthopedic medical devices.
The main products include orthopedic implanted medical devices and orthopedic surgical instruments
.
It is understood that during the national procurement of artificial joints, two joint brands under Weigao Orthopedics (Weigao Haixing and Weigao Yahua) submitted a total of 8 centralized procurement products to participate in the bidding.
The centralized procurement products all successfully won the bid
.
Industry analysts believe that although centralized procurement will reduce the profits of enterprises, for giant enterprises like Weigao Orthopedics, the premium effect of their brands and national procurement will help the sales of other products to a certain extent.
For the overall market, it will have certain advantages
.
Minimally invasive medical rose 4.
33% Hong Kong stock minimally invasive medical rose 4.
33%, as of press time, at HK $45.
750, the turnover was 32.
87 million, the turnover rate was 0.
04%, and the current total market value was 83.
266 billion
.
In the news, in addition to the proposed selection results of artificial joints, MicroPort Medical recently also issued an announcement that Shanghai MicroPort as a strategic investor will acquire 45% of Fujian Kerui Pharmaceutical held by the transferor for about 111 million yuan.
's equity
.
After the transaction is completed, Shanghai MicroPort will become the single largest shareholder of Kerui Pharmaceutical
.
Shanghai MicroPort will obtain control over the daily operations of Kerui Pharmaceutical through an agreement arrangement
.
It is reported that Kerui Pharmaceutical is an enterprise engaged in the research, development, production and sales of high value-added fermented active pharmaceutical ingredients (active pharmaceutical ingredients) such as immunosuppressants and antitumor drugs.
Its existing products include rapamycin, The active pharmaceutical ingredients of immunosuppressants, mainly tacrolimus, mycophenolate mofetil and cyclosporine, have been sold in the United States, Japan, Europe and other countries and regions
.
AK Medical and others followed suit.
In addition, AK Medical rose by 1.
57%.
As of press time, it was reported at HK $10.
320, with a turnover of 42.
72 million and a turnover rate of 0.
38%.
The current total market value is 11.
512 billion
.
It is worth mentioning that Akcome Medical has recently been favored by many institutions.
Among them, Macquarie recently released a research report saying that due to the better-than-expected bidding volume of the Centralized Drug Procurement Organization (GPO), and the company's stock price since 3 months ago high.
Down 41%, now the valuation looks attractive, upgrade the company's rating from underperform to outperform, and raise the target price by 82% to HK$12.
97
.
In addition, CMB International maintained its buy rating on the company's shares and raised the target price to HK$11.
45
.
The bank said that the results of the nationwide procurement of joint products were announced on the 14th, and the average price of the products was reduced by 82%, which was in line with the bank's expectations
.
Akcome Medical successfully won the bidding process for all four types of first-time hip and knee joint system products in the volume procurement process
.
The Group has strong innovation capabilities in 3D products and believes that it will continue to develop 3D products
.
A total of 44 companies have been selected in this centralized procurement, and the artificial joint products to be selected have an average price reduction of 82%
.
As soon as the news came out, the stock prices of related listed companies rose sharply
.
On September 14, Weigao Orthopaedic’s share price in the A-share market was at the daily limit and closed up 19%; Dabo Medical rose by the limit in the afternoon; Hong Kong stock Aikang Medical rose by more than 20%, and MicroPort Medical and Chunli Medical also increased by more than 10%.
.
Recently, the overall trend of the medical device sector is still relatively strong.
According to the news on September 17, the sector has risen.
In terms of individual stocks, Weigao Orthopedics and MicroPort Medical have risen by more than 4%.
In addition, Dabo Medical and Chunli Medical have also followed suit.
.
Weigao Orthopedics rose 4.
27% As of press time, Weigao Orthopaedic rose 4.
27% to 78.
80 yuan, with a turnover of 215 million and a turnover rate of 8.
16%.
The current total market value is 31.
520 billion
.
According to public information, Weigao Orthopaedic's main business is the research and development, production and sales of orthopedic medical devices.
The main products include orthopedic implanted medical devices and orthopedic surgical instruments
.
It is understood that during the national procurement of artificial joints, two joint brands under Weigao Orthopedics (Weigao Haixing and Weigao Yahua) submitted a total of 8 centralized procurement products to participate in the bidding.
The centralized procurement products all successfully won the bid
.
Industry analysts believe that although centralized procurement will reduce the profits of enterprises, for giant enterprises like Weigao Orthopedics, the premium effect of their brands and national procurement will help the sales of other products to a certain extent.
For the overall market, it will have certain advantages
.
Minimally invasive medical rose 4.
33% Hong Kong stock minimally invasive medical rose 4.
33%, as of press time, at HK $45.
750, the turnover was 32.
87 million, the turnover rate was 0.
04%, and the current total market value was 83.
266 billion
.
In the news, in addition to the proposed selection results of artificial joints, MicroPort Medical recently also issued an announcement that Shanghai MicroPort as a strategic investor will acquire 45% of Fujian Kerui Pharmaceutical held by the transferor for about 111 million yuan.
's equity
.
After the transaction is completed, Shanghai MicroPort will become the single largest shareholder of Kerui Pharmaceutical
.
Shanghai MicroPort will obtain control over the daily operations of Kerui Pharmaceutical through an agreement arrangement
.
It is reported that Kerui Pharmaceutical is an enterprise engaged in the research, development, production and sales of high value-added fermented active pharmaceutical ingredients (active pharmaceutical ingredients) such as immunosuppressants and antitumor drugs.
Its existing products include rapamycin, The active pharmaceutical ingredients of immunosuppressants, mainly tacrolimus, mycophenolate mofetil and cyclosporine, have been sold in the United States, Japan, Europe and other countries and regions
.
AK Medical and others followed suit.
In addition, AK Medical rose by 1.
57%.
As of press time, it was reported at HK $10.
320, with a turnover of 42.
72 million and a turnover rate of 0.
38%.
The current total market value is 11.
512 billion
.
It is worth mentioning that Akcome Medical has recently been favored by many institutions.
Among them, Macquarie recently released a research report saying that due to the better-than-expected bidding volume of the Centralized Drug Procurement Organization (GPO), and the company's stock price since 3 months ago high.
Down 41%, now the valuation looks attractive, upgrade the company's rating from underperform to outperform, and raise the target price by 82% to HK$12.
97
.
In addition, CMB International maintained its buy rating on the company's shares and raised the target price to HK$11.
45
.
The bank said that the results of the nationwide procurement of joint products were announced on the 14th, and the average price of the products was reduced by 82%, which was in line with the bank's expectations
.
Akcome Medical successfully won the bidding process for all four types of first-time hip and knee joint system products in the volume procurement process
.
The Group has strong innovation capabilities in 3D products and believes that it will continue to develop 3D products
.
